Analyst Ratings For Sarepta Therapeutics (NASDAQ:SRPT)
Today, Royal Bank Of Canada reiterated its Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $64.00.
There are 5 hold ratings, 15 buy ratings on the stock.
The current consensus rating on Sarepta Therapeutics (NASDAQ:SRPT) is Buy (Score: 2.75) with a consensus target price of $64.16 per share, a potential 29.48% upside.
Some recent analyst ratings include
- 10/3/2017-Royal Bank Of Canada Reiterated Rating of Buy.
- 10/2/2017-William Blair Reiterated Rating of Outperform.
- 10/2/2017-Instinet Reiterated Rating of Buy.
- 10/2/2017-Credit Suisse Group Reiterated Rating of Outperform.
- 10/2/2017-Robert W. Baird Reiterated Rating of Outperform.
- 10/2/2017-Morgan Stanley Upgrade from a “Equal Weight ” rating to a ” Overweight” rating.
- 9/30/2017-Leerink Swann Reiterated Rating of Outperform.
Recent Insider Trading Activity For Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT) has insider ownership of 9.60% and institutional ownership of 65.41%.
- On 7/27/2017 Douglas S Ingram, CEO, bought 47,058 with an average share price of $42.50 per share and the total transaction amounting to $1,999,965.00. View SEC Filing
- On 7/21/2017 Shamim Ruff, SVP, sold 12,138 with an average share price of $42.97 per share and the total transaction amounting to $521,569.86. View SEC Filing
- On 7/20/2017 Alexander Cumbo, SVP, sold 5,918 with an average share price of $41.00 per share and the total transaction amounting to $242,638.00. View SEC Filing
- On 7/20/2017 Edward M Md Kaye, Director, sold 10,000 with an average share price of $41.00 per share and the total transaction amounting to $410,000.00. View SEC Filing
- On 7/20/2017 Sandesh Mahatme, CFO, sold 50,000 with an average share price of $41.00 per share and the total transaction amounting to $2,050,000.00. View SEC Filing
- On 10/17/2016 Sandesh Mahatme, Insider, sold 30,000 with an average share price of $50.08 per share and the total transaction amounting to $1,502,400.00. View SEC Filing
- On 9/22/2016 David T Howton, SVP, sold 7,000 with an average share price of $60.00 per share and the total transaction amounting to $420,000.00. View SEC Filing
Recent Trading Activity for Sarepta Therapeutics (NASDAQ:SRPT)
Shares of Sarepta Therapeutics closed the previous trading session at with shares trading hands.